This site is intended for healthcare professionals

Novartis investigational novel STAMP inhibitor asciminib meets primary endpoint of Phase III chronic myeloid leukemia study.

Read time: 1 mins
Last updated:28th Jun 2021
Published:27th Aug 2020
Condition: Chronic Myelogenous Leukemia Ph+
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest